White blood cells called neutrophils, which are the first line of defense against infection, play an unexpected role by boosting antibody production, according to research led by Mount Sinai School of Medicine.
The findings suggest neutrophils have multiple roles within the immune system and function at levels previously unknown to the scientific community. The research, published in Nature Immunology, provides groundbreaking insight into possible new approaches in vaccine development for blood-borne infections and HIV.
Neutrophils are part of the so-called innate immune system—the immune system encoded at birth that remains unchanged—and are at the front lines defending against infection and inflammation. The research was led by Andrea Cerutti, MD, Professor of Medicine at Mount Sinai School of Medicine, and included an international team of investigators that also involved Irene Puga, PhD, of IMIM-Hospital del Mar in Barcelona, Spain, and Montserrat Cols, PhD, of Mount Sinai.
Researchers evaluated healthy human tissues key to the immune system to assess the abundance of neutrophils in the lymph nodes, tonsils, lymphoid tissue in the intestine, and the spleen. They found very few neutrophils in all areas but one—the region of the spleen called the marginal zone. The spleen is an organ whose primary role is as a filtration system for agents that cause infection and inflammation in the body. Looking more closely at these cells, they found that their role spanned beyond the innate immune system.
According to the study, neutrophils in the marginal zone express two molecules called BAFF and APRIL, which then activate immune cells called B-cells in the adaptive immune system, which is more sophisticated and dynamic than the innate immune system. Neutrophils signal BAFF and APRIL to reprogram B-cells to create different classes of antibodies, allowing the immune system to mount a more potent antibody response.
"Our study is important because we discovered a completely new function in an immune cell that has been studied since immunology research began," said Dr. Cerutti. "The interactivity of the neutrophils in the innate immune system with the B-cells of the more sophisticated adaptive immune system shows that neutrophils operate at a much higher level than previously thought and play a very critical role in mounting a robust response to infection."
Dr. Cerutti's team also evaluated the spleens of people with a condition called neutropenia, which is characterized by a shortage in neutrophils and a compromised immune system, and found that the marginal zones in the spleens of these patients had fewer B-cells and antibodies. This demonstrates the necessity of having neutrophils interact with marginal zone B-cells to generate an innate layer of antibody defense. The fact that the research team found an abundance of neutrophils and marginal zone B-cells in the spleens from healthy individuals, but not neutropenic patients, indicates that these cells are primed and prepared to launch multi-level antibody production in healthy humans, even in the absence of a pathogen.
"Since neutrophils boost and reprogram B-cells to strengthen the immune system regardless of whether there is an infection, we may be able to harness them in vaccine development to enhance immune protection," said Dr. Cerutti. "This has significant promise in vaccinating against blood-borne infections, as B-cells are the first line of defense to antigens in the circulatory system. If we can improve vaccines with neutrophil-activating agents, we may have a chance to boost B-cell antibody production, and improve immune protection."
With this new knowledge, Dr. Cerutti and his collaborator Meimei Shan, PhD, from Mount Sinai, are evaluating neutrophil activation and B-cell antibody production in rhesus monkeys vaccinated against Simian Immunodeficiency Virus (SIV), or HIV as it occurs in monkeys, using a vaccine that includes a chemical that activates neutrophils.
"Now that we know that neutrophils are important in the release of powerful antibody-inducing molecules, such as BAFF and APRIL, neutrophils become a potential target for protective vaccines against HIV and other infectious agents," said Dr. Cerutti. "The initial results of this SIV study are encouraging and demonstrate the enormous untapped potential of neutrophils in vaccine development."
Ongoing experiments are testing the generation of antibodies to SIV and the activation of neutrophils and B-cells in the blood, spleen, and intestinal and urogenital tracts, which are major sites of SIV/HIV entry. These measurements are conducted in animals vaccinated in the presence or absence of an agent that stimulates neutrophils. Ultimately, the ability of this vaccine to generate protection against SIV will be tested after challenging the vaccinated animals with a live virus.
This study was funded by the National Institutes of Health in Bethesda, Md.
About The Mount Sinai Medical Center
The Mount Sinai Medical Center encompasses both The Mount Sinai Hospital and Mount Sinai School of Medicine. Established in 1968, Mount Sinai School of Medicine is one of the leading medical schools in the United States. The Medical School is noted for innovation in education, biomedical research, clinical care delivery, and local and global community service. It has more than 3,400 faculty in 32 departments and 14 research institutes, and ranks among the top 20 medical schools both in National Institutes of Health (NIH) funding and by U.S. News & World Report.
The Mount Sinai Hospital, founded in 1852, is a 1,171-bed tertiary- and quaternary-care teaching facility and one of the nation's oldest, largest and most-respected voluntary hospitals. In 2012, U.S. News & World Report ranked The Mount Sinai Hospital 14th on its elite Honor Roll of the nation's top hospitals based on reputation, safety, and other patient-care factors. Of the top 20 hospitals in the United States, Mount Sinai is one of 12 integrated academic medical centers whose medical school ranks among the top 20 in NIH funding and by U.S. News & World Report and whose hospital is on the U.S. News & World Report Honor Roll. Nearly 60,000 people were treated at Mount Sinai as inpatients last year, and approximately 560,000 outpatient visits took place.For more information, visit http://www.mountsinai.org/.
Complete skin regeneration system of fish unraveled
24.04.2018 | Tokyo Institute of Technology
Scientists generate an atlas of the human genome using stem cells
24.04.2018 | The Hebrew University of Jerusalem
At the Hannover Messe 2018, the Bundesanstalt für Materialforschung und-prüfung (BAM) will show how, in the future, astronauts could produce their own tools or spare parts in zero gravity using 3D printing. This will reduce, weight and transport costs for space missions. Visitors can experience the innovative additive manufacturing process live at the fair.
Powder-based additive manufacturing in zero gravity is the name of the project in which a component is produced by applying metallic powder layers and then...
Physicists at the Laboratory for Attosecond Physics, which is jointly run by Ludwig-Maximilians-Universität and the Max Planck Institute of Quantum Optics, have developed a high-power laser system that generates ultrashort pulses of light covering a large share of the mid-infrared spectrum. The researchers envisage a wide range of applications for the technology – in the early diagnosis of cancer, for instance.
Molecules are the building blocks of life. Like all other organisms, we are made of them. They control our biorhythm, and they can also reflect our state of...
University of Connecticut researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.
Repairing major load-bearing bones such as those in the leg can be a long and uncomfortable process.
Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.
Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...
Novel highly efficient and brilliant gamma-ray source: Based on model calculations, physicists of the Max PIanck Institute for Nuclear Physics in Heidelberg propose a novel method for an efficient high-brilliance gamma-ray source. A giant collimated gamma-ray pulse is generated from the interaction of a dense ultra-relativistic electron beam with a thin solid conductor. Energetic gamma-rays are copiously produced as the electron beam splits into filaments while propagating across the conductor. The resulting gamma-ray energy and flux enable novel experiments in nuclear and fundamental physics.
The typical wavelength of light interacting with an object of the microcosm scales with the size of this object. For atoms, this ranges from visible light to...
13.04.2018 | Event News
12.04.2018 | Event News
09.04.2018 | Event News
24.04.2018 | Information Technology
24.04.2018 | Earth Sciences
24.04.2018 | Life Sciences